Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Recent Progress in Reactive Oxygen Species-Related Therapy for Disease Treatment"
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: 30 September 2023 | Viewed by 2698
Special Issue Editor
Interests: fluorescence imaging; photoacoustic imaging; microscopy; wide-field imaging; two photon imaging; second harmonic imaging; molecular imaging probes
Special Issues, Collections and Topics in MDPI journals
Special Issue in Nanomaterials: Innovation of Nanotheranostics for Precise Diagnostics and Therapeutics of Diseases
Special Issue in Biomedicines: Nanomaterial-Based Contrast Agents for Biomedical Imaging
Special Issue in Biosensors: Optical Bioimaging and Biosensing
Special Issue Information
Reactive oxygen species (ROS)-related therapy has attracted increasing attention in the last decade. It has advantages in high efficacy and negligible multiple drug resistance and holds great promise to be the next generation of treatment paradigms for cancers and even bacterial infections. The therapeutic ROS can be generated by sensitizers under a variety of stimuli, including light, ultrasound, X-rays, microwaves, chemical reactions, hyperthermia, and electric current. Among these ROS-related therapies with different stimuli, each has its advantages and disadvantages. Achieving optimal therapeutic treatment outcomes requires a customized design of medicine systems specifically for the target diseases. In addition, the combinatory of ROS-related therapy with other therapies such as chemotherapy, photothermal therapy, and radiotherapy would synergistically boost the treatment efficacy.
In this Special Issue, we systematically update the latest research progress on ROS-related therapy and its combinatory therapy. The special focus is on the state-of-the-art of medicine design, formulation technology, and their applications in the therapy of tumors and bacterial infection. This issue is a valuable platform for interested researchers to actively participate in the discussion. We accept original research articles, critical review papers, and commentaries to stimulate the further development of ROS-related therapy for disease treatment.
Research areas may include, but are not limited to, the following:
- Photodynamic therapy
- Sonodynamic therapy
- X-ray dynamic therapy
- Chemodynamic therapy
- Electric-dynamic therapy
- Hyperthermia induced dynamic therapy
- Imaging-guided therapy
- Combinatory Therapy
- Therapy of cancers and bacterial infection
- Targeted Therapy
We look forward to receiving your contributions.
Dr. Bing Guo
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.